	US 12,216,128 B2
	Methods for guiding therapy decisions in seizure disorders
Charles L. Howe, Rochester, MN (US); Benjamin D. Clarkson, Rochester, MN (US); Shailaja Kunda, Rochester, MN (US); Reghann G. LaFrance-Corey, Zumbrota, MN (US); and Eric T. Payne, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Appl. No. 16/976,592
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
PCT Filed Apr. 12, 2019, PCT No. PCT/US2019/027157 § 371(c)(1), (2) Date Aug. 28, 2020, PCT Pub. No. WO2019/200213, PCT Pub. Date Oct. 17, 2019.
Claims priority of provisional application 62/656,664, filed on Apr. 12, 2018.
Prior Publication US 2021/0140974 A1, May 13, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 38/20 (2006.01); A61P 25/08 (2006.01); C07K 14/545 (2006.01); C07K 14/715 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01)

CPC G01N 33/6869 (2013.01) [A61K 38/2006 (2013.01); A61P 25/08 (2018.01); C12Q 1/6883 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2800/52 (2013.01)]

17 Claims

1. A method for treating a subject having a seizure disorder, said method comprising determining that the subject has decreased IL-1RA function as compared to the level of IL-1RA function in corresponding normal subjects who do not have the seizure disorder, and administering to the subject a treatment that attenuates IL-1R inflammatory signaling, wherein said treatment comprises one or more of anakinra, EBI-005, and MEDI-8968.